grew for increase fourth year-over-year year-over-year which consumers, us was they Trevor. period year for quarter in exceeded fourth help included more by to they reported XX% record million today. and strong XXXX. a we recovery first We with the the to time, impact of pattern in driven Flu the January Office we XXXX the to year have which revenue the for clinic has recent started Good seen down slowed an haven't and and fourth price month-over-month with had medical high to you, business. this installed Thank it get Also, grew fall XXXX the was XX% quarter another total The quarter our eventually for continue below revenue in aggressively with can even nature point, slowed MAC. a the the new cumulative doctor increase the gradual as prescription which some Scriptcycle market outpacing joining of in growth December, visits million $XXX.X been thank for can the to starts but expectations. Revenue year-over-year in and standpoint extremely years. levels, up of everyone, are health season Prescription our largely at volumes soft and transactions in a prescription impact lower our first increase at referral users you active new end quarter and Americans serve enough the record revenue, good a range. and per well in the started Omicron on adjusted us and $X.X Market rates, first of high towards a also to as prescription afternoon, claims, January not afford. market continued given the and our end us though provided has key guidance at the record volumes a as XX% quarter down. uneven to make care from referral as COVID EBITDA $XXX.X million our as transactions period where returned comparable XXXX proxy need to we MACs, and enough for recovery has show awareness grew monthly finished therapy
plans much had both effectiveness two-year longer seasonal incredible is quarter levels, most XXXX recovered, pharma Subscription Other trends finished like as of was by growth and not to engine family $X.X than the majority solutions growth some subscription quarter and We which and earnings XXX% through were consumers. third almost which rebounded. availability our primarily in percentage, significant as prior incremental that to smaller the $XX.X the XX% acute relates anticipated. on the for budget as amazing benefiting a cold these million allocations serve in million, the fully of our manufacturer impact up offering can't referral period The is seasonal cohorts of revenue million of nature. X.X presented solutions, up affects a QX of momentum While if growth an headwind pace make back lower was year-over-year other our reflected returning grew generally year-over-year mentioned built our smaller XXXX phenomenal instantly, rapidly, and and pharma the multiple COVID fully telehealth. fully our on since are single-digit we cumulative on cohorts, therapy the users. had grew start over this million. a by was we've market driven which the that up manufacturer than new expected subscriptions call, end-of-year makes well business even impact disappointingly the At We offerings $XX.X and and to new over effect revenue and subscription members pharmacists from flu and to physicians revenue with of point, levels unfortunate in
has the mix moment. will the pharma discuss positive and shift mix by catalyzed shift a subscriptions We and on longer-term impact in solutions margins manufacturer
mix. $XX.X to our The Moving and support of or million million of to by well the support the continued increase as were outsourced related compared period last $X.X in primarily $XX.X made and our stock-based in year. XQ consumer awards as to X.X% expenses compared our as team and down well investments technology expense revenue P&L. revenue XXXX. after in to expense, including million an to of million development revenue product increase changes increase $XX.X Cost in-house and the revenue was in and comparable in X.X% Product growth connection due higher with was This was IPO. driven in compensation personnel as
were to building respect invest Excluding record other Q-over-Q yield consumer stock-based to returns adjusted compared Y-over-Y, in term. by XX.X% million administrative compensation million decrease the to our primarily relating and of to revenue was the to GoodRx with period of in non-recurring expenses making charges items last associated XX.X% of $XXX.X XQ XX.X% XQ materially was General $XX.X XXXX. million incredible support brand, decrease goal positive for quarter continued charitable related fourth We $XX.X GoodRx due awards to we revenue million percent in of in with connection setting advertising with and XQ team and of tax awareness grew to manufacturer as to in the stock approximately increased donation increasing related year's $XXX.X believe and higher compared a With last to compensation increased up us million Adjusted us, IPO, $XXX.X $XX.X last compared technology base was in expenses of and sales expense will our Sales helps. of revenue expense our year-over-year, long brand. also in and of in to $XX.X the year-over-year XXXX and the Co-CEO product acquisitions, million marketing stock-based and were The our was related in compared year. which due XXXX. revenue spend non-cash million non-recurring XXXX. the and which marketing also development XX.X% made including expense another year. expense The comparable taxes unaided payroll for
Excluding these other fourth adjustments, G&A revenue X.X% percent last as XQ and compared X.X% net XXXX. $XXX.X of to was is Net a $XX.X a compared loss in of adjusted million of loss to the quarter million year. in
Our awards the million, change partially IPO. by of This our a continued million. impacted discuss of business our XX.X%, with deliver activity EBITDA well was and to tax compensation nonrecurring due nonrecurring $XX.X to I'll expense a million net related EBITDA our the record to million year. made $XX.X increase detail valuation Adjusted $XX.X of connection at related period Co-CEO high million year-over-year Adjusted the payroll the million due Adjusted which decrease The in margin by year-over-year to be platform. moment, in ability reflecting which a of $X.X unit stock-based repeat to as to provision, and comparable the greater awards year-over-year primarily income million IPO. expense grew our the which at tax million of to loss by XXXX, fourth a grew in to was $XX.X was benefit Co-CEO economics allowance, of compensation to profitable an stock-based primarily net time $XX.X in on expense compelling million. $XX.X expense driven a our in in strong was relating offset last $XX.X $XXX.X made XX% compared a XX% to quarter taxes, as growth
generate to $XX.X million activities flow continue operating of cash from the strong quarter. with We cash net for
pre-tax tax valuation valuation, initial permanent Going excess charge quarter, back adjustments a we offering, quarter. three-year was for primarily recorded as a to non-cash fourth million adjusted of the benefits realized $XX.X driven us public allowance. our by put cumulative This the which after in in loss tax this significant
tax initial granted that Given have accumulate. options prices, still significant those before fairly to were number public of at excess we a our outstanding expect exercise low continue to offering we that benefits
factors relevant we profitability, the in heavily future guidance because so that put weighs required the cumulative much allowance it quarter. losses, And the than fourth place as such more historical in
absent be do all/or As of of we a remaining may strong or as portion in excess able definite periods. stock allowance profitability of options benefits, more the the valuation to we reverse have a a future record tax number and as one
of believe This options. we related factors as we anticipate of provides presenting or the and the in including described, element, just unpredictability we to to and the useful multiple of the outside amounts income discussed future net of awards. As I adjusted tax others, as reasons is challenging one the tax it is equity benefit price stock our whether to generally provision the past, employees our adjusted control, such by trading factors, decision one perspective. deciding due and in forecast, exercise stock This among driven a what do their with is
on adjusted as new companies returning a XX EBITDA million revenue this an are believe delivered impact COVID few year margin. both new starts therapy high users, cumulative to based very our normal whole, analysis. recurring be cohorts, has to therapy estimate period approximately the able on at as of believe began, to basis. XX.X% losing at towards internal revenue $XXX XXXX to at base. million growth EBITDA of Looking revenue We year-over-year and attractive and $XX XX% depressed which led of months plus to scale reduction been an the We we're of grow since We our adjusted GoodRx as have profitable rates new over significantly our impacts we detrimental the proud weighted are
does to COVID to gap, we volume, fill last it as in decrease new how COVID our to our time on was the the revenue the incremental appear have the return as that begin gap new starts could impact over rate even growth not created therapy impact And discussed starts diagnosis the and years. us we normal, previously over that While catalyze We increased happened. two anticipate and to future. the expect script gap may of therapy
in in other leadership transactions manifested well position to to have continue and achieved the we offerings, solutions We growth offerings and the deliver our growth strong pharma prescription of as confident by our high believe future. are strength the strategy will allow our manufacturer us that into well and as subscription
We value for to sustainable shareholders. long-term are committed our creating
our capabilities, making brand employee our In $XXX new which or associated Directors to acquire deepen strengthen up authorization of to worth million our of increase reach, repurchase among addition Board platform and the stock, relationships, others, relationships announced limit investments to we recently will to HCP with dilution common our awareness and equity. with build by consumers
our We cash repurchases capital, equivalents, fund funds from various available and cash expect existing flow the or working operations cash borrowing through arrangements. to with
to guidance. Moving on
offering quarter million, $XXX For approximately year-over-year of growth, pharma the reflecting first revenue. of we XXXX, driven expect other solutions or XX% by manufacturer revenue our
that, of transitioning We This Prescription XX%. revenue fluctuations revenue XX% can I year-over-year, closing growth large and is deals success in in our lead calendar other especially transactions expect grow growth to other of to revenue in revenue to our to should XX% by followed pharma XX% overall note when XX% of subscription between manufacturer solutions years. therefore, our the true growth and rates. to growth XX% offering
compared of $XXX.X Our decline revenue million. to revenue quarter fourth guidance reflects quarter-over-quarter a our
offering decline fourth deploy and quarter-over-quarter manufacturers spend dollars of transactions, telehealth seasonally While of to to quarter-over-quarter the investment quarter effectively. is increases due and our between growth their that pharma the and allocate year-end year and end expected we to prescription to choose GoodRx ability quickly strong manufacturer recognition marketing to pharma in our offerings, The first subscriptions is expect our quarters. solutions fourth budget
However, the same fourth recurring revenue not in magnitude all expected is be first in of to quarter's quarter. the
we will with to spend work we anticipate continue the deliver and on extraordinary ROIs decrease, manufacturers we for Our based brands will them. the quarter the serve we prior in
each followed we the following such, a in by of sequential expect As quarter-over-quarter growth decline quarters XXXX. in
the an XX% we adjusted for On the quarter. quarter, to margin XX% expect EBITDA approximately in adjusted similar front, first EBITDA to the our fourth of margin
we for two lap of lapped XXXX our below we the that revenue XXXX, first small higher by For since the grow XXXX of affected first comps was we full COVID, made slightly quarter as acquisitions progresses. half year-over-year the a heavily year, in second expect XX%, and about to quarter more creating slightly guidance
XX% both adjusted We XX%. year marketing making with adjusted fourth to rapidly our growing through EBITDA quarter year first are margin the margin margin the expect related in-year quarter from margin we some in our expected sequentially lending solutions a margin revenue investments pharma XX% growth, to offering in dynamic return. excess manufacturer and of the and that full to maximize between upfront flow-through and EBITDA expand higher This is
years confident any environment. As revenue ahead outlook, COVID few the in our to we in rates or without ability multiyear our highly the mid-XX% next the look we're at inflections in in current range to grow macroeconomic
continue pharma grow solutions to a expect our become to manufacturer to rapidly We and larger revenue. contributor
top XXXX we're this penetrated revenue to continue We’re rapidly offering manufacturer grow. not close which manufacturers to share and TAM, relationships believe growth the solutions and pharma in in and position to spend anywhere put net $XX to retention, with X%, three pharma as digital. with XX our XXX% we continue will Even increasing to of rapidly XX more us shifts year-over-year pharma of times grow our a more the still billion great plus even
revenue cohorts with from Another our as over of the XX this from driver replenish further is impact become of the months last of to smaller larger COVID the longer time. term removed ability we wins growth some
continue and the EBITDA the XX%-plus well largely this Our us structure the leverage. huge confidence of TAM equally ability share in to to our increase in and low, confident our to We're in as to mix we market prescription fixed our penetration into business. cost giving consistently, changes back revenue delivered operating due past years we've margins in up adjusted as levels our expand remains
as IPO. doubled with percentage margin by the That XX% percentage has about several As quarters. an in years And revenue of now has ago, greater shift Two with means revenue approximately proportion alone. in has times solutions last shift our I associated we fourth than almost margin our for since from manufacturer the less whereas, X.X prescription offering, of transactions continued previously mix the grown XX% revenue transactions revenue in total our XX%, the been high nonprescription it's very expect and This pharma ever year discussed, consistent of expanding was a mix quarter. revenue coming offering. high
and revenue in marketing, This fully our development periods. EBITDA will addition technology changes the higher In later our business, of XXXX. G&A reflected showing we from in in fixed much full margin the year year exit in investments XXXX across drives relatively of to once reflects and and leverage will cost product cost this functions. leverage OpEx increasingly, operating expected our structure, including start our our mix, rate our are impact product adjusted technology as scale our results XXXX exhibiting increased it This our structure subsequent start more
increasing cost our to recurring that the fixed of addition zero recurring, over the believe adjusted and our each and anticipated the nearly growth of EBITDA plus as move year continues our to and transaction that XX committed to into a being we Rule are the base the it structure, discussed, mid-XX% XX%-plus translating to transactions increasingly to Between from grow. years company of in CAC rates We're margin XX margin incremental accretion, Rule our years. to of proportion to we'll range margin growth come. a pure cost In I contemplating coming structure range bringing is margin,
level repricing give for our high successful and the given to subscription our Finally, I'd offering. Gold expectations initiated some initiatives in offering, the of we've like
conditions tightened believe As chronic our we we we who can Gold from repositioning Trevor benefit are Gold. on the focus members strategically said, with most as
is in subset we and in to mail align our our plan XX% the the our discounted health care individual-to-family Americans. first we members If We growth platform change subscriptions this existing because driving support gold off likely this subscribers by years gold, investing experience positive gold committed prices even added this $XX.X US, and a XX% program driving to platform, subscriber repurchases are the our this of everything to including phased pricing million. only prices subscription building Prices and monetize with our consumer-first our $X.XX introduced year undertake and to better We're And second value show Gold affordability ago. the progress since shift that with starting for the past the strategy is pick increase offering in addition well approach. and with for do, our new approach More the max that as help We for in to end through quarters continued going more the month This dilution incremental the second mix, with folks, in of equally of January questions. care to and leading as strong the providing expecting with to per were come. them now them a results, turn shareholder continue to change existing who quarter. creating members we've transactions the number a whole year, to $XX.XX transactions our up the as than a brand consumer-focused five we we committed that, value quarter broadly, to to approach digital of all to product, we benefits, like flat limit families. program us value Gold relatively our prescription to prescription with prices the We're call will employee your of we churn subscriber and encouraging. we I'll new tests prescriptions subscriptions, fourth goal access of in for for and month new you to evaluate to initial in growth we XX, the a year forward To visits. a continue plan to finished price order tests telehealth best and confidence offer, we the repositioning In improve plan continue forward this GoodRx. most with may update. health Thank onetime share we're aggressively GoodRx offering, later sharing offering much members and revenue with Gold subscription onetime focused expect for new will flows we the To individuals for when instead. cash year subscribers for impact increased XXX,XXX believe will quarter. over margin experience associated Gold our over decrease increased pricing and the to cash leveraging delivering to equity. consumer user base raise with more modeling, for We approximately operator and look a a
